CMS Open Payments · Program Year 2024
Avid Radiopharmaceuticals, Inc.
Avid Radiopharmaceuticals, Inc. reported $1,116,283.69 across General Payments, Research, and Ownership to 38 physicians and teaching hospitals across 51 transactions.
- $1.1M Above-median payer
- All-tracks total
- 51 Below-median volume
- Transactions
- 38 Below-median reach
- Recipients
- −$54.4K
- General Payments vs PY2023
Avid Radiopharmaceuticals, Inc. reported $1,116,283.69 across all CMS Open Payments tracks (General + Research + Ownership) to 38 physicians and teaching hospitals in Program Year 2024 - ranking #597 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $8,052.81, averaging $29.4K per recipient.
How Avid Radiopharmaceuticals, Inc.'s $1.1M all-tracks total breaks down
Avid Radiopharmaceuticals, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
16/100
Total payments
F
20/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer avid-radiopharmaceuticals-inc Avid Radiopharmaceuticals, Inc.
$1.1M · #597/1,925 · 0.0% industry · PY2024
- TOT $1.1M
- RANK #597
- SHARE 0.0%
- TXN 51
- RCP 38
- CAT 2
- GEN $8.1K
- ΔGEN −$54.4K
- TOP1 29.1%
- PY 2024
Volume peers
Nearest volume peer: Guard Medical SAS ($1.1M)
Avid Radiopharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Avid Radiopharmaceuticals, Inc.'s CMS-reported General Payments decreased by $54.4K (−87.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: AVID RADIOPHARMACEUTICALS, INC.PY2023: AVID RADIOPHARMACEUTICALS, INC.PY2024: Avid Radiopharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $62,405.90
- PY2024
- $8,052.81
What the Data Shows for Avid Radiopharmaceuticals, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Avid Radiopharmaceuticals, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
The 2-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Travel and Lodging" at $6.4K, accounting for 79.6% of this company's General Payments and 13 transactions.
General Payment Breakdown by Type
Avid Radiopharmaceuticals, Inc. made 2 types of general payments. "Travel and Lodging" is the largest category at $6.4K, 79.6% of General Payments.
How Avid Radiopharmaceuticals, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Travel and Lodging | $6.4K | 13 | 79.6% |
| Food and Beverage | $1.6K | 25 | 20.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $7,242.70 (89.9%) of $8,052.81 in this company's General Payments records across 25 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Avid Radiopharmaceuticals, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Kevin Patrick Weber
$2,341.31 across 4 reported transactions
- 2
Joseph William Sam
$1,370.21 across 4 reported transactions
- 3
Maria Rosana Ponisio
$1,301.10 across 3 reported transactions
- 4
Giuseppe Esposito
$1,248.70 across 3 reported transactions
- 5
Ernest Gordon Depuey III
$981.38 across 4 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Avid Radiopharmaceuticals, Inc.'s spend rank (#597 of 1,925, top 31% by spend) and concentration rank (#789 of 1,838, top 43% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Current Health Inc. : $10.2K total payments, HHI 1822
- Lsi Solutions Inc : $274.8K total payments, HHI 1813
- Photocure Inc : $179.4K total payments, HHI 1810
- LeMaitre Vascular, Inc. : $311.5K total payments, HHI 1805
- RMC Orthopedic & Surgical, Inc. : $13.5K total payments, HHI 1800
- NS Pharma, Inc. : $103.1K total payments, HHI 1796
- Avid Radiopharmaceuticals, Inc. (this company) : $8.1K total payments, HHI 1793
- Applied Medical Technology Inc : $176.9K total payments, HHI 1791
- Ignite Orthopedics, LLC : $705.4K total payments, HHI 1790
- BioPro, Inc. : $101.9K total payments, HHI 1788
- Lazarus 3D : $1.2K total payments, HHI 1788
- exocad America, Inc. : $54.9K total payments, HHI 1781
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Avid Radiopharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Avid Radiopharmaceuticals, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Avid Radiopharmaceuticals, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Arrow International, Inc.
Medartis Inc.
Lumenis BE inc
Avanos Medical
Fisher & Paykel Healthcare Limited
Put this to use
Avid Radiopharmaceuticals, Inc. ranks #597 of 1,925 by all-tracks total payments, led by "Travel and Lodging".
- See where Avid Radiopharmaceuticals, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Travel and Lodging" spend across every manufacturer, not just Avid Radiopharmaceuticals, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.